This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.
Downloadable materials for your patients
Below are links to downloadable materials that may be useful as a resource to pass onto your patients who have been prescribed Venetoclax.
Patient guide for VEN in 1L
UK-VNCCLL-240267
Patient guide for VEN in R/R
UK-VNCCLL-240268
Patient guide for VEN in all lines
UK-VNCCLL-240269
A guide to completing treatment with VENCLYXTO
UK-VNCCLL-240270
VEN+O dosing chart
UK-VNCCLL-240271
VEN+R dosing chart
UK-VNCCLL-240272
Understanding patients perspectives
Seeing things from the patient perspective is an important aspect of patient-centered care. Our video featuring patient perspectives and stories illustrating the CLL treatment journey is here to view.
1L, 1st line; CLL, Chronic lymphocytic leukaemia; O, obinutuzumab; R, rituximab; R/R, relapsed/refractory; VEN, VENCLYXTO.
You are advised to read the Prescribing Information and Summary of Product Characteristics to evaluate patient suitability for VENCLYXTO.
VENCLYXTO PRESCRIBING INFORMATION
VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (GB)
VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (NI)
UK-VNCCLL-240305. Date of preparation: June 2024.
